ATE469969T1 - Menschlicher anti-mensch-mcp-1-antikorper sowie antikorperfragment davon - Google Patents

Menschlicher anti-mensch-mcp-1-antikorper sowie antikorperfragment davon

Info

Publication number
ATE469969T1
ATE469969T1 AT03795363T AT03795363T ATE469969T1 AT E469969 T1 ATE469969 T1 AT E469969T1 AT 03795363 T AT03795363 T AT 03795363T AT 03795363 T AT03795363 T AT 03795363T AT E469969 T1 ATE469969 T1 AT E469969T1
Authority
AT
Austria
Prior art keywords
human
mcp
antibodies
fragment
antibody
Prior art date
Application number
AT03795363T
Other languages
English (en)
Inventor
Kazuhisa Sugimura
Toshihiro Nakashima
Tsukasa Nishihara
Original Assignee
Chemo Sero Therapeut Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemo Sero Therapeut Res Inst filed Critical Chemo Sero Therapeut Res Inst
Application granted granted Critical
Publication of ATE469969T1 publication Critical patent/ATE469969T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
AT03795363T 2002-09-12 2003-09-10 Menschlicher anti-mensch-mcp-1-antikorper sowie antikorperfragment davon ATE469969T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002267184 2002-09-12
PCT/JP2003/011560 WO2004024921A1 (ja) 2002-09-12 2003-09-10 ヒト抗ヒトｍｃｐ−１抗体及び該抗体フラグメント

Publications (1)

Publication Number Publication Date
ATE469969T1 true ATE469969T1 (de) 2010-06-15

Family

ID=31986692

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03795363T ATE469969T1 (de) 2002-09-12 2003-09-10 Menschlicher anti-mensch-mcp-1-antikorper sowie antikorperfragment davon

Country Status (11)

Country Link
US (1) US7342106B2 (de)
EP (1) EP1538207B1 (de)
JP (1) JP4426449B2 (de)
KR (1) KR20050042801A (de)
CN (1) CN1681926A (de)
AT (1) ATE469969T1 (de)
AU (1) AU2003262051B2 (de)
CA (1) CA2497804A1 (de)
DE (1) DE60332847D1 (de)
DK (1) DK1538207T3 (de)
WO (1) WO2004024921A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
AU2004314693B2 (en) 2003-09-26 2011-04-07 Alza Corporation Drug coating providing high drug loading and methods for providing the same
PE20110071A1 (es) * 2005-05-19 2011-01-31 Centocor Inc Anticuerpos anti-mcp-1, composiciones y metodos
US8114964B2 (en) * 2005-05-19 2012-02-14 Centocor, Inc. Anti-MCP-1 antibodies, compositions, methods and uses
JP5379692B2 (ja) 2006-11-09 2013-12-25 プロビオドルグ エージー 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
US8906680B2 (en) 2006-12-22 2014-12-09 Ablynx N.V. Amino acid sequences directed against chemokines and polypeptides comprising the same for the treatment of chemokine-related diseases and disorders
CN101668525A (zh) 2007-03-01 2010-03-10 前体生物药物股份公司 谷氨酰胺酰环化酶抑制剂的新用途
DK2142514T3 (da) 2007-04-18 2015-03-23 Probiodrug Ag Thioureaderivater som glutaminylcyclase-inhibitorer
CN101802211B (zh) 2007-08-02 2014-10-01 诺维莫尼公司 抗正常t细胞表达和分泌活化调节因子(rantes)抗体及其使用方法
RU2547595C2 (ru) 2008-08-18 2015-04-10 Пфайзер Инк Антитела против ccr2
US8518406B2 (en) 2008-08-20 2013-08-27 Probiodrug Ag Antibodies directed against pyroglutamate monocyte chemoattractant protein-1 (MCP-1 N1pE)
JP5934645B2 (ja) 2009-09-11 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
CN102791704B (zh) 2010-03-10 2015-11-25 前体生物药物股份公司 谷氨酰胺酰环化酶(qc, ec 2.3.2.5)的杂环抑制剂
EP2560953B1 (de) 2010-04-21 2016-01-06 Probiodrug AG Hemmer der glutaminylzyklase
JP6050264B2 (ja) 2011-03-16 2016-12-21 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
WO2016025789A1 (en) * 2014-08-15 2016-02-18 PixarBio Corporation Compositions for inhibting inflammation in a subject with a spinal cord injury and methods of using the same
CN110087530A (zh) 2016-12-07 2019-08-02 普罗根尼蒂公司 胃肠道检测方法、装置和系统
WO2018112264A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
DK3461819T3 (da) 2017-09-29 2020-08-10 Probiodrug Ag Inhibitorer af glutaminylcyklase
EP3883635A1 (de) 2018-11-19 2021-09-29 Progenity, Inc. Verfahren und vorrichtungen zur behandlung einer krankheit mit biotherapeutika
EP3870261B1 (de) 2019-12-13 2024-01-31 Biora Therapeutics, Inc. Einnehmbare vorrichtung zur abgabe eines therapeutischen mittels an den magen-darm-trakt
CN112358547A (zh) * 2020-09-30 2021-02-12 浙江大学 抗人cxcl-2单克隆抗体3-d3及其编码基因和应用
CN112778414B (zh) * 2020-12-31 2022-04-15 中南大学湘雅二医院 cBIN1抗体及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0967399A (ja) * 1995-08-30 1997-03-11 Mitsui Toatsu Chem Inc 抗ｍｃｐ−１ヒトモノクローナル抗体
JP4298051B2 (ja) * 1999-04-13 2009-07-15 和久 杉村 抗ｍｃｐ−１抗体認識ペプチドミミックス、その製造方法およびその用途
US7309693B2 (en) 2000-05-26 2007-12-18 Kensuke Egashira Preventives and remedies for pulmonary hypertension
GB0016138D0 (en) * 2000-06-30 2000-08-23 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
CA2497804A1 (en) 2004-03-25
AU2003262051A1 (en) 2004-04-30
US20060246069A1 (en) 2006-11-02
EP1538207A1 (de) 2005-06-08
CN1681926A (zh) 2005-10-12
JP4426449B2 (ja) 2010-03-03
EP1538207A4 (de) 2006-05-24
DK1538207T3 (da) 2010-07-05
WO2004024921A1 (ja) 2004-03-25
JPWO2004024921A1 (ja) 2006-01-12
EP1538207B1 (de) 2010-06-02
US7342106B2 (en) 2008-03-11
AU2003262051B2 (en) 2008-09-25
KR20050042801A (ko) 2005-05-10
DE60332847D1 (de) 2010-07-15

Similar Documents

Publication Publication Date Title
ATE469969T1 (de) Menschlicher anti-mensch-mcp-1-antikorper sowie antikorperfragment davon
RS52332B (en) HUMAN ANTI-NGF NEUTRAL ANTIBODIES AS SELECTIVE NGF SIGNAL ROUTE INHIBITORS
CR8698A (es) Anticuerpos monoclonales al factor de crecimiento de hepatocito
RS52889B (sr) Terapijsko humano anti-il-1r1 monoklonsko antitelo
PE20030846A1 (es) Anticuerpos para cd40
CY1118063T1 (el) ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ΑΝΘΡΩΠ1ΝΗΣ IgE ΥΨΗΛΗΣ ΣΥΓΓΕΝΕΙΑΣ
ATE476992T1 (de) Neutralisierbares epitop von hgf und an dieses bindende neutralisierender antikörper
CY1112277T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
EA200501286A1 (ru) МОЛЕКУЛЫ АНТИТЕЛ СО СПЕЦИФИЧНОСТЬЮ К ЧЕЛОВЕЧЕСКОМУ IL-1β
RS52860B (en) ANTI-ILT7 ANTITELO
RS53058B (en) SP35 ANTIBODIES AND THEIR APPLICATIONS
ATE530195T1 (de) Bispezifische einzelketten-fv-antikörper-moleküle und anwendungsverfahren dafür
PE20020319A1 (es) ANTICUERPOS PARA IL-1ß HUMANA
NZ604090A (en) Human anti-b7rp1 neutralizing antibodies
ATE479710T1 (de) Bispezifische antikörper
PE20110797A1 (es) Anticuerpos anti mn
RS80704A (en) ANTI- av?6.ANTIBODIES
DE602005022928D1 (de) Antikörper gegen gpnmb und ihre verwendungen
ZA200702879B (en) Single domain antibodies against TNFR1 and methods of use therefor
RS50858B (sr) Anti-tnf antitela, kompozicije, metode i njihove upotrebe
NZ595450A (en) Antibodies to M-CSF
CA2469833A1 (en) Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
DK1308507T3 (da) Monoklonalt antistof mod HCV-kerneantigen
ATE517920T1 (de) Humanisierte antikörper gegen interferon-alpha- rezeptor-1 (ifnar-1)
ITMI20031127A1 (it) Anticorpi anti-hgf-r e loro uso

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1538207

Country of ref document: EP